EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets

Paschalis Karakasis iD, Panagiotis Theofilis iD, Panayotis K Vlachakis iD, Panagiotis Korantzopoulos iD, Dimitrios Patoulias iD, Antonios P Antoniadis, Nikolaos Fragakis iD

International Journal of Molecular Sciences · 30.12.2024 · 26 (1) · 209

DOI: 10.3390/ijms26010209 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.12.2024. Verfasst von Paschalis Karakasis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Atria. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atrial fibrosis is a hallmark of atrial cardiomyopathy and plays a pivotal role in the pathogenesis of atrial fibrillation (AF), contributing to its onset and progression. The mechanisms underlying atrial fibrosis are multifaceted, involving stretch-induced fibroblast activation, oxidative stress, inflammation, and coagulation pathways. Variations in fibrosis types—reactive and replacement fibrosis—are influenced by patient-specific factors such as age, sex, and comorbidities, complicating therapeutic approaches. The heterogeneity of fibrosis leads to distinct electrophysiological abnormalities that promote AF via reentrant activity and enhanced automaticity mechanisms. Despite advancements in imaging, such as late gadolinium enhancement CMR and electroanatomical mapping, challenges in accurately quantifying fibrosis persist. Emerging therapeutic strategies include antifibrotic agents targeting the renin–angiotensin–aldosterone system, novel pathways like TGF-β signaling, and cardio-metabolic drugs like SGLT2 inhibitors and GLP-1 receptor agonists. Innovative interventions, including microRNA modulation and lipid nanoparticle-based therapies, show promise but require validation. Knowledge gaps remain in correlating clinical outcomes with fibrosis patterns and optimizing diagnostic tools. Future research should focus on precise phenotyping, integrating advanced imaging with molecular biomarkers, and conducting robust trials to evaluate antifibrotic therapies’ efficacy in reducing AF burden and related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart AtriaHumansFibrosisAnimalsBiomarkers

Stichwörter der Autor:innen

GLP1 receptor agonistsSGLT2 inhibitorsarrhythmogenic mechanismatrial fibrillationatrial fibrosisinflammationprotease-activated receptor inhibitors

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
  • First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • First Department of Cardiology, School of Health Sciences, Faculty of Medicine, University of Ioannina, 45500 Ioannina, Greece.
  • Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, 54642 Thessaloniki, Greece.

ORCID-Profile: Paschalis Karakasis, Panagiotis Theofilis, Panayotis K Vlachakis, Panagiotis Korantzopoulos, Dimitrios Patoulias, Nikolaos Fragakis

Zitieren

APA

Karakasis, P., Theofilis, P., Vlachakis, P. K., Korantzopoulos, P., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2024). Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 26(1), 209. https://doi.org/10.3390/ijms26010209

Vancouver

Karakasis P, Theofilis P, Vlachakis PK, Korantzopoulos P, Patoulias D, Antoniadis AP, et al. Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. International Journal of Molecular Sciences. 2024;26(1):209. doi:10.3390/ijms26010209

BibTeX
@article{Karakasis2024,
  author = {Karakasis, Paschalis and Theofilis, Panagiotis and Vlachakis, Panayotis K and Korantzopoulos, Panagiotis and Patoulias, Dimitrios and Antoniadis, Antonios P and Fragakis, Nikolaos},
  title = {Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {26},
  number = {1},
  pages = {209},
  doi = {10.3390/ijms26010209}
}
Kostenlos starten →